Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid

Journal of Neurochemistry

Volumn 89, Issue 2, 2004, Pages 484-493

  Wenk, Gary L ^a   McGann Gramling, Kristin ^a   Hauss Wegrzyniak, Beatrice ^a   Ronchetti, Daniela ^b   Maucci, Raffaella ^b   Rosi, Susanna ^a   Gasparini, Laura ^b   Ongini, Ennio ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Nicox Research Institute   (Italy)

Author keywords

Alzheimer's disease; Ferulic acid; NCX 2057; Neuroinflammation; Nitric oxide

Indexed keywords

3 [(4 HYDROXY 3 METHOXYPHENYL) 2 PROPENOIC ACID 4 NITROXY]BUTYL ESTER; ANTIOXIDANT; FERULIC ACID; LIPOPOLYSACCHARIDE; NCX 2057; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN VENTRICLE; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ELECTRON SPIN RESONANCE; ENCEPHALITIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MICROGLIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TEMPORAL LOBE;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BUTANES; CHRONIC DISEASE; COUMARIC ACIDS; DENTATE GYRUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENCEPHALITIS; ENTORHINAL CORTEX; ISOQUINOLINES; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRO COMPOUNDS; RATS; RATS, INBRED F344; TEMPORAL LOBE; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA;

EID: 1942519702     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02359.x     Document Type: Article

References (66)

1. Aisen P. S., Schafer K. A., Grundman M., Pfeiffer E., Sano M., Davis K. L., Farlow M. R., Jin S., Thomas R. G. and Thal L. J. (2003) Effects of refecoxib or naproxen vs. placebo on Alzheimer disease progression. JAMA 289, 2819-2826.
2. Akiyama H., Barger S., Barnum S. et al. (2000) Inflammation in Alzheimer's disease. Neurobiol. Aging 21, 383-421.
3. Aldini G., Carini M., Orioli M., Facino R. M. and Wenk G. L. (2002) Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: a LC-MS study. Life Sci. 71, 1487-1500.
4. Albin R. L. and Greenamyre J. T. (1992) Alternative excitotoxic hypotheses. Neurol. 42, 733-738.
5. Behl C. (1999) Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. 5, 301-323.
6. Bogdan C. (2001) Nitric oxide and the immune response. Nat. Immunol. 2, 907-916.
7. Brune K. and Neubert A. (2001) Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin. Exp. Rheumat. 1, S51-S57.
8. Cagnin A., Brooks D. J., Kennedy A. M., Gunn R. N., Myers R. and Turkheimer F. E. (2001) In-vivo measurement of activated microglia in dementia. Lancet 358, 461-467.
9. Cannon R. O., Schechter A. N., Panza J. A., Ognibene F. P., Pease-Fye M. E., Waclawiw M. A., Shelhamer J. H. and Gladwin M. T. (2001) Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J. Clin. Invest. 108, 279-287.
10. Carini M., Aldini G., Stefani R., Orioli M. and Facino R. M. (2001) Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J. Pharm. Biomed. Anal. 2, 509-518.
11. Chen Y., McCarron R. M., Golech S., Bembry J., Ford B., Lenz F. A., Azzam N. and Spatz M. (2003) ET-1 and NO-mediated signal transduction pathway in human brain capillary endothelial cells. Am. J. Physiol. Cell Physiol. 284, C243-C249.
12. Coleman J. W. (2002) Nitric oxide: a regulator of mast cell activation and mast-cell mediated inflammation. Clin. Exp. Immunol. 129, 4-10.
13. Coyle J. and Kershaw P. (2001) Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiat. 49, 289-299.
14. Etminan M., Gill S. and Samii A. (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Br. Med. J. 327, 128-132.
15. Faraci F. M. and Sobey C. G. (1999) Role of soluble guanylate cyclase in dilator responses of the cerebral microcirculation. Brain Res. 821, 368-373.
16. Fiorucci S. (2001) NO-releasing NSAIDs are caspase inhibitors. Trends Immunol. 2, 232-235.
17. Frautschy S. A., Hu W., Kim P., Miller S. A., Chu T., Harris-White M. E. and Cole G. M. (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging 2, 993-1005.
18. Friedlich A. L. and Butcher L. L. (1994) Involvement of free oxygen radicals in β-amyloidosis: a hypothesis. Neurobiol. Aging 1, 443-455.
19. Fukumoto L. R. and Mazza G. (2000) Assessing antioxidant and prooxidant activities of phenolic compounds. J. Agric. Food Chem. 48, 3597-3604.
20. Gahtan E. and Overmier J. B. (1999) Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli. Neurosci. Biobehav. Rev. 23, 615-633.
21. Gladwin M. T., Ognibene F. P., Pannell L. K., Nichols J. S., Pease-Fye M. E., Shelhamer J. H. and Schechter A. N. (2000) Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation. Proc. Natl. Acad. Sci. USA 9, 9943-9948.
22. Graf E. (1992) Antioxidant potential of ferulic acid. Free Radic. Biol. Med. 13, 435-448.
23. Hauss-Wegrzyniak B., Dobrzanski P., Stoehr J. D. and Wenk G. L. (1998a) Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 780, 294-303.
24. Hauss-Wegrzyniak B., Baker L. B., Del Soldato P., Pepeu G. and Wenk G. L. (1998b) Peripheral administration of novel anti-inflammatories can attenuate the effect of chronic inflammation within the CNS. Brain Res. 815, 36-43.
25. Hauss-Wegrzyniak B., Vraniak P. and Wenk G. L. (1999) The effects of a novel NSAID upon chronic neuroinflammation are age dependent. Neurobiol. Aging 20, 305-313.
26. Hauss-Wegrzyniak B., Galons J. P. and Wenk G. L. (2000) Quantitative volumetric analysis of brain magnetic resonance imaging from rat with chronic neuroinflammation and correlation with histology. Exp. Neurol. 16, 347-354.
27. Hauss-Wegrzyniak B., Lynch M. A., Vraniak P. D. and Wenk G. L. (2002) Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Exp. Neurol. 176, 336-341.
28. Hooper D. C., Kean R. B., Scott G. S., Spitsin S. V., Mikheeva T., Morimoto K., Bette M., Rohrenbeck A. M., Dietzschold B. and Weihe E. (2001) The central nervous system inflammatory response to neurotrophic virus infection is peroxynitrite dependent. J. Immunol. 167, 3470-3477.
29. Hosoda A., Ozaki Y., Kashiwada A., Mutoh M., Wakabayashi K., Mizuno K., Nomura E. and Taniguchi H. (2002) Syntheses of ferulic acid derivatives and their suppressive effects on cyclooxygenase-2 promoter activity. Bioorg. Med. Chem. 10, 1189-1196.
30. Huang M. T., Lysz T., Ferraro T., Abidi T. F., Laskin J. D. and Conney A. H. (1991) Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 51, 813-819.
31. In 'T Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijin C. M., Stijnen T., Breteler M. M. B. and Stricker B. H. C. (2001) Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. New Engl. J. Med. 346, 1515-1521.
32. In 'T Veld B. A., Launer L. J., Breteler M. M. B., Hofman A., Stricker B. H. (2002) Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiologic Rev. 24, 248-268.
33. Jantzen P. T., Connor K. E., DiCarlo G., Wenk G. L., Wallace J. L., Rojiani A., Coppola D., Morgan D. G. and Gordon M. N. (2002) Microglial activation and Aβ deposit reduction caused by a nitro-NSAID, NCX-2216 in APP+PS1 transgenic mice. J. Neurosci. 22, 2246-2254.
34. Kanski J., Aksenova M., Stoyanova A. and Butterfield D. A. (2002) Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. J. Nutr Biochem. 13, 273-281.
35. Keeble J. E. and Moore P. K. (2002) Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. 13, 295-310.
36. Kikuzaki H., Hisamoto M., Hirose K., Akiyama K. and Taniguchi H. (2002) Antioxidant properties of ferulic acid and its related compounds. J. Agric. Food Chem. 50, 2161-2168.
37. Law A., Gauthier S. and Quirion R. (2001) Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res. Rev. 3, 73-96.
38. Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A. and Cole G. M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2, 8370-8377.
39. Lowry O. H., Rosenbrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with folin phenol reagent. J. Biol. Chem. 193, 265-275.
40. Ma Q., Kinneer K., Ye J. and Chen B. J. (2003) Inhibition of nuclear factor B by phenolic antioxidants: interplay between antioxidant signaling and inflammatory cytokine expression. Mol. Pharmacol. 6, 211-219.
41. McGeer E. G. and McGeer P. L. (1999) Inflammation of the brain in Alzheimer's disease: implications for therapy. J. Leukocyte Biol. 65, 409-415.
42. Murakami A., Kadota M., Takahashi D., Taniguchi H., Nomura E., Hosoda A., Tsuno T., Maruta Y., Ohigashi H. and Koshimizu K. (2000) Suppressive effects of novel ferulic acid derivatives on cellular responses induced by phorbol ester, and by combined lipopolysaccharide and interferon-γ. Cancer Lett. 15, 77-85.
43. Napoli C., Aldini G., Wallace J. L. et al. (2002) Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc. Natl Acad. Sci. USA 9, 1689-1694.
44. Ogiwara T., Satoh K., Kadoma Y., Muratami Y., Unten S., Atsumi T., Sakagami H. and Fujisawa S. (2002) Radical scavenging activity and cytotoxicity of ferulic acid. Anticancer Res. 22, 2711-2717.
45. 3H]PK11195 binding in gerbil hippocampus after transient forebrain ischemia. J. Neurosci. Res. 64, 493-500.
46. Rozovsky I., Finch C. E. and Morgan T. E. (1998) Age-related activation of microglia and astrocytes-in vitro studies show persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiol. Aging 19, 97-103.
47. Sakai S., Ochiai H., Nakajima K. and Terasawa K. (1997) Inhibitory effect of ferulic acid on macrophage inflammatory protein-2 production in a murine macrophage cell line, RAW264.7. Cytokine 9, 242-248.
48. Sano M., Ernesto C., Thomas R. G. et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 33, 1216-1222.
49. Scharf S., Mander A., Ugoni A., Vajda F. and Christophidis N. (1999) A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 5, 197-201.
50. Schubert P., Morino T., Miyazaki H., Ogata T., Nakamura Y., Marchini C. and Ferroni S. (2000) Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. NY Acad. Sci. 903, 224-233.
51. Scott B. C., Butler J., Halliwell B. and Aruoma O. I. (1993) Evaluation of the antioxidant actions of ferulic acid and catechins. Free Radic. Res. Comm. 1, 241-253.
52. Shen B., Jensen R. G. and Bohnert H. J. (1997) Mannitol protects against oxidation by hydroxyl radicals. Plant Physiol. 115, 527-532.
53. Smith M. A., Hirai K., Hsiao K., Pappolla M. A., Harris P. L. R., Siedlak S. L., Tabaton M. and Perry G. (1998) Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70, 2212-2215.
54. Stephenson D. T., Schober D. A., Smalstig E. B., Mincy R. E., Gehlert D. R. and Clemens J. A. (1995) Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J. Neurosci. 1, 5263-5274.
55. Stewart W. F., Kaas C., Corrada M. and Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
56. Thiel V. E. and Audus K. L. (2001) Nitric oxide and blood-brain barrier integrity. Antiox. Redox Signal. 3, 273-278.
57. Vaananen P. M., Keenan C. M., Grisham M. B. and Wallace J. (1992) Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1, 227-240.
58. Van Gool W. A., Weinstein H. C., Scheltens P. K. and Walstra G. J. (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet 35, 455-460.
59. Wang Y.-J., Pan M.-H., Cheng A.-L., Lin L.-I., Ho Y.-S., Hsieh C.-Y. and Lin J.-K. (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharmaceut. Biomed. Anal. 1, 1867-1876.
60. Wenk G. L. and Hauss-Wegrzyniak B. (2001) Animal models of chronic neuroinflammation as a model of Alzheimer's Disease, in Inflammatory Events in Neurodegeneration (Bondy, S. and Campbell, A., eds), pp. 83-87. Prominent Press, Scottsdale.
61. Wenk G. L., McGann K., Fiorucci S., Mencarelli A., Hauss-Wegrzyniak B. and Del Soldato P. (2000) Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur. J. Pharmacol. 402, 77-85.
62. Wenk G. L., Rosi S., McGann K. and Hauss-Wegrzyniak B. (2002) A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. Eur. J. Pharmacol. 45, 319-324.
63. Xu K. Y. (2000) Nitric oxide protects nitric oxide synthase function from hydroxyl radical-induced inhibition. Biochem. Biophys. Acta 1481, 156-166.
64. Yan J.-J., Cho J.-Y., Kim H.-S., Kim K.-L., Jung J.-S., Huh S.-O., Suh H.-W., Kim Y.-H. and Song D.-K. (2001) Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br. J. Pharmacol. 13, 89-96.
65. 2 receptor antagonists. Neurology 59, 880-886.
66. Zhang Z., Wei T., Hou J. and Li G., Yu, S. and Xin W. (2003) Iron-induced damage and apoptosis in cerebellar granule cells: attenuation by tetramethylpyrazine and ferulic acid. Eur. J. Pharmacol. 467, 41-47.